Novo Nordisk has said that CagriSema is well-tolerated, and the most common adverse events were gastrointestinal (GI) related
10.1080/19490976.2023.2297860 21 ChungL.OrbergE
What makes copper peptides particularly interesting is their mechanism of action
Its clinical and histological features resemble other liver disorders, reducing the usefulness of biopsies
Disclosures: Alvi Islam: Nothing to Disclose, Luis Antonio Daz: Nothing to Disclose, Francisco Idalsoaga: Nothing to Disclose, Rokhsana Mortuza: Nothing to Disclose, Winston Dunn: Nothing to Disclose, Yanming Li: Nothing to Disclose, Ashwani Singal: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Carolina Ramirez-Cadiz: Nothing to Disclose, Wei Zhang: Nothing to Disclose, Steve Qian: Nothing to Disclose, Joaquin Cabezas: Gilead: Advisor, Gilead: Speaking and Teaching, Abbvie: Speaking and Teaching, Gilead: Grant/Research Support, Ines Garcia: Nothing to Disclose, Shiv Kumar Sarin: Nothing to Disclose, Rakhi Maiwall: Nothing to Disclose, Prasun Jalal: Nothing to Disclose, Fatima Higuera-de-la-Tijera: Nothing to Disclose, Lubomir Skladan: Worwag: Speaking and Teaching, ProMed: Speaking and Teaching, Abbvie: Speaking and Teaching, Gilead: Speaking and Teaching, RegPharm: Speaking and Teaching, Natalia Bystrianska: Nothing to Disclose, Ana Clemente: Nothing to Disclose, Diego Rincon: Nothing to Disclose, Kristina Chacko: Nothing to Disclose, Pamela Yaquich: Nothing to Disclose, Meritxell Cots: Nothing to Disclose, Guadalupe Garcia-Tsao: Nothing to Disclose, Juan Abraldes: Gilead: Grant/Research Support, 89bio: Consultant, Boston Pharmaceuticals: Consultant, Novo Nordisk: Consultant, Boehringer Ingelheim: Consultant, Astra Zeneca: Consultant, Agomab: Consultant, Terumo: Speaking and Teaching, Cook: Grant/Research Support, Patrick Kamath: Sequana: Advisor, NovoNordisk: Advisor, Marco Arrese: Aztra Seneca: Steering Commitee, Inventiva: Consultant, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor, Juan Pablo Arab: Nothing to Disclose 1531 IMMUNE CHECKPOINT B7-H4 PROMOTES CHOLANGIOCARCINOMA GROWTH VIA TGFΒ-INDUCED STROMAL REMODELING, UNVEILING A NOVEL TARGETABLE TUMOR-STROMA AXIS Emily Bramel 1 Matias Facciuto 2 Miguel Torres-Martin 3 Eric Park 2 Romain Donne 2 Ramja Sritharan 2 Li Chen 4 Sumera Ilyas 5 Mathieu Petitjean 4 Anna Tocheva 2 Swan Thung 6 Alexander Tsankov 2 Amaia Lujambio 2 Daniela Sia 2 , 1 Icahn School of Medicine at Mount Sinai, 2 ISMMS, 3 IDIBAPS, 4 PHARMANEST, 5 Mayo Clinic Rochester, 6 Icahn School of Medicine at Mount Sinai (ISMMS) Background: Intrahepatic Cholangiocarcinoma (iCCA) is a desmoplastic cancer with largely ineffective therapies
Fecal microbiota transplantation in amyotrophic lateral sclerosis: clinical protocol and evaluation of microbiota immunity axis
